If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baqsimi™ (glucagon) nasal powder
3mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
BAQSIMI™ (glucagon) nasal powder: Hypersensitivity and Allergic Reactions
Hypersensitivity and allergic reactions have been reported with glucagon. Baqsimi (glucagon nasal powder) is contraindicated in patients with a prior hypersensitivity reaction to glucagon.
Baqsimi is contraindicated in patients with known hypersensitivity to glucagon or to any of the excipients in Baqsimi.1
Allergic reactions have been reported with glucagon.1
Allergic reactions with glucagon have included generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension.1
Baqsimi is contraindicated in patients with a prior hypersensitivity reaction.1
Enclosed Prescribing Information
BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly
1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
Baqsimi = Baqsimi™ (glucagon) nasal powder
Date of Last Review: July 24, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
